 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
HIV Salvage Therapy: Research
See also: Structured HIV Treatment Interruptions
- Management of Treatment-Experienced Patients: A Summary of Key CROI 2008 Research (February 11, 2008)
From The Body PRO - Another Look at TITAN and DUET: How Will They Change Clinical Practice? (July 25, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - Efficacy and Safety of Darunavir-Ritonavir Compared With That of Lopinavir-Ritonavir at 48 Weeks in Treatment-Experienced, HIV-Infected Patients in TITAN: A Randomised Controlled Phase III Trial (July 7, 2007)
Study shows greater viral suppression among darunavir patients after 48 weeks.
In The Lancet - Adding Etravirine to Darunavir/Ritonavir Improves Virologic Suppression, DUET Studies Show (July 6, 2007)
From aidsmap.com - New Treatment Paradigms for Treatment-Experienced Patients (November 13, 2006)
In 8th International Congress on Drug Therapy in HIV Infection - Tipranavir/Ritonavir-Associated Hepatotoxicity Common, But Resolves Over Time (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Virologic Outcomes With Tipranavir + Ritonavir Prove to Be Durable Out to 96 Weeks in the RESIST Studies (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Whereas Other PIs Fail, Tipranavir Maintains High-Level Potency Against Key PI Resistance Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Optimizing Therapy for Patients With Multidrug-Resistant HIV (July 31, 2006)
To read PDF, click here
From Insight Medical Communications Inc. - New Developments in HIV Drug Resistance and Options for Treatment-Experienced Patients (May 15, 2006)
Coverage of the 4th European HIV Drug Resistance Workshop and the 12th Annual Conference of the British HIV Association
Free CME/CE credit available for physicians, nurses and pharmacists.
From The Body PRO - Researchers Examine Use of Artificial Intelligence to Select Ideal Regimens for Treatment-Experienced Patients (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Four-NRTI Regimen May Provide Simple Option for Treatment-Experienced Patients on Unduly Complex or Toxic Treatment (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Virologic Suppression Between Six and 18 Months on New Regimen Can Predict Long-Term Outcomes (December 16, 2005)
In addition, patients who previously had a treatment interruption appear less likely to succeed on their current regimen.
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Lamivudine Monotherapy Better Than Treatment Interruption in Rescue Patients With M184V (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - HIV JournalView: Putting Atazanavir + Ritonavir on the Map (July/August 2005)
A study finds the combo is comparable to lopinavir/ritonavir in patients with some baseline protease inhibitor resistance.
From The Body PRO - Lopinavir/Ritonavir Plus Efavirenz -- Worthy or Wacky? (July/August 2005)
A French study examines an NRTI-sparing regimen containing two of the most powerful antiretrovirals.
From The Body PRO - Triple PI Therapy May Help Heavily Treatment-Experienced Patients, But Pill Burden a Concern (October 2004)
Quick recap of a study in JAIDS.
In HIV Treatment ALERTS!, from The Center for AIDS - Tenofovir and Efavirenz Show Promise as Two-Drug Maintenance Regimen (July 26, 2004)
The so-called "COOL Study" examined this novel two-drug regimen in patients who had already achieved viral suppression on traditional, three-drug HAART.
From aidsmap.com - Intermittent Drug Switching Can Resensitize Patients With Multidrug-Resistant HIV-1 (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO - New Dosing Regimen for Ritonavir-Boosted Atazanavir in Treatment-Experienced Patients; Revisions Made to Packaging Insert (July 7, 2004)
From U.S. Food and Drug Administration - Salvage Therapy II Think Tank: Integration of Salvage Research Into Existing Networks and Structures (Summer 2004)
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS - Salvage Therapy II Think Tank: Meeting Summary (Summer 2004)
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS - Salvage Therapy II Think Tank: Proof of Concept Studies/Translational Research; New Hypotheses (Summer 2004)
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS - Salvage Therapy II Think Tank: Regulatory Issues and Challenges in Salvage Therapy (Summer 2004)
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS - Salvage Therapy II Think Tank: The Future of Salvage Therapy: Monitoring Systems for Patient Outcomes (Summer 2004)
For a complete list of articles covering this think tank, click here.
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS - Drug Monitoring, NRTI Activity Help Predict Lopinavir/Ritonavir Response in Experienced Patients (February 11, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Little Difference Between Resistance Testing Methods in Treatment-Experienced Patients (February 10, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Single-Drug Interruption May Be Useful in Identifying Still-Active Drugs in Heavily Treated Patients (February 10, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Triple-PI Regimens for Rescue Treatment (February 10, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Boosted Atazanavir Similar to Boosted Lopinavir in Treatment-Experienced Patients (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration - Adding ddI Achieves Fall in Viral Load in HAART Patients With Resistance (September 14, 2003)
From aidsmap.com - Risk of Death Following Triple-Class Virological Failure (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - To Switch or Not to Switch: When Is It a Question? (September 2003)
Steven Deeks, M.D., offers his wisdom on what options remain for patients who have failed one, two or many HAART regimens.
In The PRN Notebook - Ritonavir-Boosted Atazanavir Demonstrates Comparable Viral Load Reduction to Kaletra (August 15, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Enfuvirtide Benefits Confirmed at 48 Weeks (July 16, 2003)
Resistance testing is also found to be a reliable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Atazanavir in Treatment-Experienced Patients (July 15, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - The Inhibitory Quotient in Tipranavir/Ritonavir (July 14, 2003)
Therapeutic drug monitoring and phenotypic resistance testing are also found to be a valuable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Tipranavir/Ritonavir's Resistance Profile in Multiple-Protease-Inhibitor-Experienced Patients (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - An Interview With Dr. Cal Cohen on Highlights From the 10th Conference on Retroviruses and Opportunistic Infections (April 4, 2003)
In AIDS Treatment News, from AIDS Treatment News - Atazanavir Resistance: Use as Second- or Third-Line PI Should Not Be Ruled Out (April 1, 2003)
Evidence that this drug in development may be more than a first-line treatment.
From aidsmap.com - Structured Treatment Interruption to Increase Response to Salvage Therapy (Spring 2003)
From STEP's conference review of Retrovirus 2003.
In STEP Perspective, from Seattle Treatment Education Project - The Context Study: Efficacy and Safety of GW433908/RTV in PI-Experienced Subjects With Virological Failure (24 Week Results) (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Tipranavir/Ritonavir Demonstrates Potent Efficacy in Multiple Protease Inhibitor-Experienced Patients: BI 1182.52 (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Baseline and On-Treatment Susceptibility to Enfuvirtide Seen in TORO 1 and TORO 2 to 24 Weeks (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Effect of Amprenavir Hypersusceptibility on the Response to APV/Ritonavir-Based Therapy in ART-Experienced Adults Selected by Baseline Susceptibility (ESS40006): 24-Week Data (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Correlation of Viral Load Reduction and Plasma Levels in Multiple Protease Inhibitor-Experienced Patients Taking Tipranavir/Ritonavir in a Phase IIB Trial: BI 1182.52 (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Pharmacokinetic Parameters of Atazanavir/Ritonavir When Combined to Tenofovir in HIV Infected Patients With Multiple Treatment Failures: A Substudy of Puzzle2-ANRS 107 Trial (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Salvage Strategies and STI at the 10th Annual Retrovirus Conference (January/February 2003)
In GMHC Treatment Issues, from Gay Men's Health Crisis - Research From the 42nd ICAAC: High Lopinavir Levels Predict High Lipids (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Safety Profile of Tenofovir DF in Treatment-Experienced Patients From Randomized, Placebo-Controlled Clinical Trials (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Predictors of Long-Term Response to Therapy Resumption After Treatment Interruption in HIV-1 Infected Patients Failing Antiretroviral Therapy (November 19, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - International HIV Workshop on Management of Treatment-Experienced Patients (November 2002)
A summary of the workshop's presentations.
In Hopkins HIV Report - Data From the 14th International AIDS Conference: Treatment-Experienced Patients (October 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Enfuvirtide in Combination With an Optimized Background Regimen vs. OB Alone in Patients With Prior Experience or Resistance to Each of the Three Classes of Approved Antiretrovirals (July 12, 2002)
In The XIV International AIDS Conference, from The Body PRO - Tenofovir DF: A 48-Week Final Analysis From a Phase III Randomized, Double Blind, Placebo Controlled Study in Antiretroviral Treatment-Experienced Patients (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO - Phenotypic and Genotypic Profiles Predict Week 24 Responses to an Abacavir-Containing Salvage Regimen (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Preliminary Results of Intensification Therapy With Amprenavir/Ritonavir in Two Different Doses: 1,200/200 QD vs. 600/100 BID in Heavily Pretreated Patients Failing HAART (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Safety Profile of Tenofovir DF in Antiretroviral Treatment-Experienced Patients From Randomized, Double-Blind, Placebo-Controlled Clinical Trials (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Successful Intensification of Antiretroviral Therapy With Abacavir in Clinical Practice (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Decreased Plasma Concentrations of Amprenavir and Lopinavir in HIV Patients on This Combination (July 8, 2002)
In The XIV International AIDS Conference, from The Body PRO - Anti-HIV Therapy Update: STI and Third-Line Therapy (March 2002)
In Project Inform Perspective, from Project Inform - Selected Highlights From Retrovirus: Medications for the Treatment Experienced (February 28, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Efficacy, Safety and Amprenavir: Pharmacokinetic Responses of Twice-Daily APV and Ritonavir Regimens in HIV-1 Infected Treatment-Experienced Adults for 48 Weeks (ESS40006) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Management of "Salvage" Antiretroviral Therapy (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Antiretroviral Therapy for Previously Treated Patients (December 2001)
Summary of an August 2001 New England Journal of Medicine editorial.
In Body Positive, from Body Positive - Efficacy of Lopinavir in Heavily Pretreated Patients (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO - Antiviral Activity and Tolerability of PEG-Intron in HIV Patients Failing HAART (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Impact of Treatment Interruption on Plasma Viral Load, CD4 Count and Virtual Phenotypes (Virco) in HIV Patients Who Failed Multiple Courses of Antiretroviral Therapy (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - FDA Discusses Trial Design for Salvage Therapy (April 2001)
In TAGline, from Treatment Action Group - FDA Gives Salvage Therapy Testing a Push Forward (March 23, 2001)
In AIDS Treatment News, from AIDS Treatment News - Treatment of Antiretroviral-Experienced Patients: New Data From the 8th Retrovirus Conference (March 1, 2001)
In Hopkins HIV Report - Amprenavir and Ritonavir: Intra-Individual Comparison of Different Doses and Influence of Concomitant NNRTI on Steady-State Pharmacokinetics in HIV-Infected Patients (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Indinavir/Ritonavir Versus Indinavir in Combination With AZT/3TC for Treatment of HIV in Nucleoside-Experienced Patients: A Randomized, Open-Label Trial (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - New Drugs for the Treatment-Experienced Patient (September 2000)
In The PRN Notebook - Forty-Eight Week Analysis of Patients Receiving T-20 as a Component of Multi-Drug Salvage (July 13, 2000)
In The XIII International AIDS Conference, from The Body PRO - More Data on Higher-Dose Lopinavir/Ritonavir (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO
  |
  |